Overview

Effect of Anti-IgE in Chronic Urticaria

Status:
Completed

Trial end date:
2007-09-01

Target enrollment:

Participant gender:

Summary

This study is being done to find out if a drug called Xolair (omalizumab), an anti-IgE antibody, is safe and effective for people with chronic urticaria (hives) with persistent symptoms in spite of taking antihistamines.

Phase:

Phase 2

Details

Lead Sponsor:

Johns Hopkins University

Collaborator:

Genentech, Inc.

Treatments:

Omalizumab